Sanofi Pasteur
174, av. de France
Paris
75013
France
Tel: 33-1-53-77-4076
Fax: 33-1-53-77-4174
Website: http://en.sanofi-aventis.com/
189 articles about Sanofi Pasteur
-
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
-
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
6/22/2021
Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio, a clinical-stage messenger RNA therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
Sanofi Pasteur and Translate Bio have partnered to develop a novel messenger RNA vaccine for COVID-19, the disease caused by the novel coronavirus.
-
To date, there are more than 72,000 confirmed and suspected cases of COVID-19 and 1,023 deaths from COVID-19, most in mainland China.
-
The site location is in Swiftwater, Pennsylvania.
-
FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas
5/1/2019
The U.S. Food and Drug Administration approved Dengvaxia® for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection.
-
Here’s a look at this week’s calendar for decisions coming down from the U.S. Food and Drug Administration (FDA).
-
BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance
10/30/2017
BERG today announced a new research effort with Sanofi Pasteur, the influenza vaccine global leader.
-
Sanofi Pasteur Inks $645 Million RSV Deal With AstraZeneca PLC's MedImmune
3/6/2017
-
Sanofi Pasteur Announces The Availability of Quadracel DTaP-IPV Vaccine For Children 4 Through 6 Years Of Age In The U.S.
1/31/2017
-
Sanofi Pasteur and Merck & Co. Terminate Joint Vaccines Biz in Europe, Effective Immediately
1/3/2017
-
Sanofi Pasteur Abandons Bladder Cancer Drug
11/18/2016
-
Sanofi Pasteur Release: High-Dose Influenza Vaccine With Evidence Of Superior Efficacy* In Older Adults: Now In Canada
10/13/2016
-
Sanofi Pasteur Nabs $43 Million U.S. Funding to Speed Up Zika Vaccine Development
9/27/2016
-
Dyadic Stock Tanks Amid Reports of Partnership Termination With Sanofi Pasteur
8/9/2016
-
Sanofi Pasteur Ships First Of Its 2016-2017 Seasonal Influenza Vaccine Doses In United States
7/26/2016
-
New Four-Strain Influenza Vaccine, VaxigripTetra, Regulatory Dossier From Sanofi Pasteur Now Approved In Europe
6/23/2016
-
Terrapinn Release: Experts From Merck & Co., GlaxoSmithKline, Pfizer, Sanofi Pasteur And More To Debate Breakthroughs For Vaccines For Ebola, Zika And Cancer.
3/7/2016